Regularized glioma expression score associates with survival across archived cohorts
Source check: Source checked. Not independent scientific confirmation.
Finding: A stepwise-Cox plus ridge model constructed from a supplied glioma expression signature was associated with survival across nine archived cohorts. The final model was selected using average validation-cohort performance, so those cohorts do not provide an untouched external test. The narrow result is a retrospective score–outcome association, not a verified treatment target or clinical-benefit claim.
Technology: Mime; stepwise Cox selection; ridge-regularized survival learning
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- A fitted ridge survival model following feature selection supplies the patient score whose observed survival association is assessed; software availability and visualization alone are not the represented result.
- Test and result
- Mime compared 117 combinations across one development and eight additional glioma cohorts. The selected STRICOM score separated survival outcomes using cohort median scores, and adjusted analyses considered established clinical/molecular covariates.
- Limitation / still unknown
- All additional cohorts informed final model selection and model-ranking comparisons; performance can be optimistic. Risk cutoffs are cohort-specific. Input signatures and clinical cohorts are reused, not new randomized or prospective evidence. The SDC1 example includes previously reported biology and is not represented as a newly discovered causal mechanism. Operational perturbation procedures and supplementary experimental details were not reviewed.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11269309/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Exact primary front and selected computational/clinical Methods and corresponding high-level Results; operational laboratory protocols excluded from review.
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.